Clinical Trials Logo

Clinical Trial Summary

The overall goal of this project is to identify, assess and longitudinally monitor subjects who are interested in participating in this study. Participants will enroll through a platform named PaWei, and provide informed consent prior to any study activities. PaWei will collect a variety of information, including participants' demographic information, overall health, family history of Parkinson's Disease, other clinical information (clinical drug use, drug efficacy, and comorbid disorders), mood status, sleep, diet, exercise, memory complaints, online cognitive tests, the Short-Form 8-Item Parkinson's Disease Questionnaire (PDQ-8), Movement Disorder Society-Unified Parkinson's Disease Rating Scale IB & II (MDS-UPDRS IB & II), Non-Motor Symptom Aassessment Scale for Parkinson's Disease (NMSS) , Hoehn and Yahr Scale, and other scales related to quality of life, etal---all through self-reported online questionnaires. Participants will also be asked to return to the PaWei every 3 months at regular intervals, to complete follow-up scales related to quality of life, and neuropsychological assessments, etal. Anyone with Parkinsonian Disorders is welcome to participate.


Clinical Trial Description

In April 2017, the investigators launched a platform named PaWei which contains an iOS and Android smartphone application for patients and doctors. The platform connects patients, doctors and researchers by establishing communication and data transfer between the cloud platform and the mobile applications over the internet. The PaWei app is made available for free to download through the Apple App Store and Android Market. Through national outpatient service, advertisement and community outreach, potential participants will be directed to the PaWei APP. The overall goal of this project is to identify, assess and longitudinally monitor subjects who are interested in participating in this study. Participants will enroll through the PaWei APP, and provide informed consent prior to any study activities. The PaWei APP will include: 1. Information about the National Registry Study (who is eligible to participate, the goals of the project and other relevant information about investigators and sponsors involved in the Initiative). 2. Frequently Asked Questions (FAQs) such as "How will my information be used?", "How will patient information be safeguarded?", "What information will be requested?", "How much time will be required for registration and testing?" will be addressed for participants. 3. General information about Parkinsonian Disorders. The National Registry Study will be a large, online database of volunteers who are interested in participating in this study. Anyone with Parkinsonian Disorders is welcome to join the Registry. 1. Participants will provide their email address or telephone number and create an account and username with the Registry. 2. The Registry will send an automatic email or short message to the participant to verify their email address or telephone number. 3. Participants will read the online Information Sheet and will be asked to provide their consent by clicking either "I consent" or "I decline." Participants who decline to participate in the Registry will be not included in our study. 4. Participants who give their consent will be permitted to continue through the registration process, which includes completing a battery of questionnaires designed to obtain a general understanding of participants health, medical history wellbeing. 5. In addition to questionnaires, participants will be able to complete online scales related to quality of life, and cognitive assessments. 6. Participants will be given the option to elect a Caregiver and/or Study Partner (CASP) to enrich their study profile. 7. Video recordings: Participants are asked to perform finger tapping, hand movements, and walking in MDS-UPDRS III test after being instructed by the video example, and then to upload the videos to the PaWei APP. The severity of motor dysfunctions on those videos can be judged by clinicians, and be potentially quantified in the future by AI technology under development. 8. Data validation: (1) The quality control of raw data is the initial step of data analysis for any successful research. In PaWei platform, the investigators take a strategy of assessing the data quality by identifying poor-quality data, like incomplete data and illogical data based on the logistic verification about consistency of relevant questions. (2) Automated feedback loops are employed with this strategy to enable real-time detection of incomplete data or illogical data, which can be used to improve data collection quality. 9. Participants may be referred to other research studies and/or clinical trials. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03649503
Study type Observational [Patient Registry]
Source Huashan Hospital
Contact Jian Wang, MD
Phone 86-21-52888160
Email wangjian336@hotmail.com, Wangjian_hs@fudan.edu.cn
Status Recruiting
Phase
Start date October 1, 2018
Completion date September 30, 2033

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT04704349 - Latest Imaging SPECT System Evaluation Phase 1 N/A
Completed NCT01385592 - Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Phase 2
Completed NCT05608915 - External vs Internal-triggered Augmented-reality Visual Cues to Treat Freezing of Gait N/A
Recruiting NCT04871464 - Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease Phase 4
Withdrawn NCT04847609 - GentleCath Air (Urinary Self-catheterization) - Pain in Female Patients With Neurological Vesico-sphincter Disorders
Completed NCT05356845 - Oral Health, Orofacial Function and Oral Health Care in Patients With Parkinson's Disease
Completed NCT02021903 - Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies N/A
Completed NCT03065192 - Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease Phase 1
Not yet recruiting NCT04727658 - Linac FRACtionated Radiosurgical THALamotomie in Tremors (FRACTHAL) Phase 2
Recruiting NCT02696603 - Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower) N/A
Completed NCT01491932 - Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Phase 2
Recruiting NCT05906719 - Machine Vision Based MDS-UPDRS III Machine Rating
Completed NCT03156647 - Alpha-synuclein Level in Saliva to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome
Recruiting NCT02994719 - Gait Analysis in Neurological Disease
Completed NCT04974034 - Movement Disorders Analysis Using a Deep Learning Approach
Terminated NCT00686699 - Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) Phase 2
Completed NCT04925622 - Complex Eye Movements in Parkinson's Disease and Related Movement Disorders
Recruiting NCT06193252 - Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands N/A
Enrolling by invitation NCT06283043 - Effect of Motor Function, Depression and Sleep Quality on Attention in Parkinson's Disease